month

Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness

TARRYTOWN, N.Y. & MADISON, N.J.--(BUSINESS WIRE)--Jun 28, 2007- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and WyethPharmaceuticals, a division of Wyeth (NYSE: WYE), today announcedpositive results from a three-month open-label extension study ofsubcutaneous methylnaltrexone for the treatment of opioid-inducedconstipation (OIC) in patients with advanced illness. The resultsare sched...

A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients

Final Results from Exploratory Phase IIa Clinical Trial in Type 2Diabetes Patients Announced TORONTO, June 28, 2007 /PRNewswire-FirstCall/ - TransitionTherapeutics Inc. ("Transition") , today announces the results fromits exploratory Phase IIa clinical trial indicating that 4-weeks ofdaily treatments with gastrin-based therapy, E1-I.N.T.(TM), showedsustained reductions in blood glucose co...

Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia

PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced that additional Phase 2 clinicaltrial results for Hematide(TM) were presented at the European RenalAssociation-EDTA Congress being held in Barcelona, Spain by Iain C.Macdougall, M.D., a Hematide investigator from Kings College,London. Dr. Macdougall's poster included data in previously-treateddialy...

Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration

PARIS--(BUSINESS WIRE)--Jun 11, 2007 - Regulatory News-Ipsen(Paris:IPN) announced today that the preliminary data from theongoing phase III study for its investigational 4-month formulationof triptorelin do not support the expected sustainable blood levelsof triptorelin for a duration of 4 months in all patients.Therefore, Ipsen has decided not to perform the secondadministration as planned...

Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimer's Disease Study

SAN FRANCISCO, June 05, 2007 /PRNewswire-FirstCall/ --Medivation, Inc. today announced that it will hold a teleconferenceat 8:30 a.m. Eastern time on Monday, June 11, to discuss top-line12-month results from its randomized, double-blind,placebo-controlled Phase 2 clinical trial of Dimebon(TM), its leadproduct candidate, in Alzheimer's disease. Rachelle Doody, M.D., Ph.D., lead inve...

12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced that DAYTRANA(TM) (methylphenidate transdermal system),the first and only non-oral medication approved for treatment ofAttention Deficit Hyperactivity Disorder (ADHD) in children aged 6to 12 years, provided significant improvement in symptom controland tolerability, according to results of a 12-month open-labelstudy pre...

Abbott Announces Positive Nine-Month Results From the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

Absorbable Stent Continues to Show Promise as Future-GenerationTechnology BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Abbotttoday announced positive results from ABSORB, the world's firstclinical trial evaluating the safety and performance of a fullybioabsorbable drug eluting stent platform for the treatment ofcoronary artery disease. Nine-month results from the first 30pati...

Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Professor IanMeredith, M.D., Monash Medical Centre, Melbourne, Australia, onTuesday presented positive nine-month results from the MedtronicRESOLUTE clinical trial at the EuroPCR meeting in Barcelona, Spain,with data showing a low number of adverse cardiac events and noprotocol-defined stent thrombosis. The next-generation Medtronic(NYSE:MDT...

XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting

Trial Included One of the Most Challenging Patient PopulationsStudied of Any Drug-Eluting Stent (DES) Clinical Trial BARCELONA and MENLO PARK, Calif., May 22, 2007/PRNewswire-FirstCall/ -- XTENT, Inc. announces positive six-monthfollow-up data from the CUSTOM II clinical trial, which assessedthe safety and efficacy of the company's investigational CustomNX(R) drug-eluting stent (DES) syst...

Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial

EDMONTON, May 07, 2007 /PRNewswire-FirstCall/ - Isotechnika Inc.today announced the audited three month results, reviewed by theData Monitoring Committee, of the first third of the patientstreated in its Phase 2b de novo kidney transplant trial for theCompany's lead immunosuppressive drug, ISA247. This interim analysis is based upon the assessment of the first116 patients enrolled....

Prospective Model Outlined Potential Time and Cost Savings of Once-Monthly Anemia Treatment

DALLAS, Texas and NUTLEY, N.J., April 23, 2007 /PRNewswire/ --An activity-based cost analysis demonstrated that if a renal anemiatreatment administered once every four weeks replaced thrice weeklyadministration of epoetin alfa, hemodialysis centers may save anestimated 802 nursing hours and more than $44,000 per year per 100patients. These data, from a multi-center prospective analysis of...

Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease

PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced results to date from two separatePhase 2 clinical trials of Hematide(TM) in dialysis andnon-dialysis chronic kidney disease (CKD) patients. The data showedthat in treatment naive, non-dialysis patients Hematide couldcorrect anemia when administered monthly at an appropriate dose.Similarly, the data...

UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age

UCB Announces Positive Top-Line Phase III Results forKeppra® as Adjunctive Therapy for Partial Onset Seizures inPaediatric Patients from One Month to Less than Four Years ofAge BRUSSELS, Belgium - April 20, 2007 - UCB today announcedpositive top-line results from a phase III, double-blind,randomized, multi-centre, placebo-controlled study evaluating theefficacy and tolerabilit...

New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting

ADDISON, Texas, April 19, 2007 /PRNewswire/ -- New clinicaltrial results for heart transplant patients will be released at theupcoming International Society for Heart and Lung Transplantation(ISHLT) 27th Annual Meeting and Scientific Sessions at the HiltonSan Francisco, April 25-28, 2007. Results show promise for efficacyand safety of immunosuppression therapy and lower incidences ofacut...

Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207 for BPH

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 18, 2007 - NymoxPharmaceutical Corporation (NASDAQ: NYMX) announced todaycompletion of a new 42 month follow-up study of NX-1207 for benignprostatic hyperplasia (BPH). The study evaluated symptomaticprogress of U.S. patients involved in the Company's two Phase 1-2studies initiated in 2003. Individuals in the study were assessedfor symptomatic im...

Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons

Company Announces Extension of Phase I/IIa Trial to 9 mg DosageLevel HOPKINTON, Mass., April 16, 2007 /PRNewswire-FirstCall/ --Boston Life Sciences announced today that clinical data on its leadnerve repair therapy, Cethrin(R), were presented in the Neurotraumaand Critical Care Scientific Session at the 75th Annual Meeting ofthe American Association of Neurological Surgeons (AANS) inWash...

Abbott Announces Positive Six-Month Results From the World's First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent

Abbott's Bioabsorbable Stent Technology Holds Promise asFuture-Generation Treatment Option for Physicians Treating Patientswith Coronary Artery Disease ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ --Abbott today announced positive results from ABSORB, the world'sfirst clinical trial evaluating the overall safety and performanceof a fully bioabsorbable drug- eluting stent platf...

Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimer's Disease Conference

SAN FRANCISCO, March 19, 2007 /PRNewswire-FirstCall/ --Medivation, Inc. today announced that six-month results from itsrandomized, double-blinded, placebo-controlled Phase 2 efficacytrial of Dimebon(TM) in patients with mild-to-moderate Alzheimer'sdisease demonstrated that patients treated with Dimebon weresignificantly improved compared to patients taking placebo on allfive efficacy end...